Loading...
Loading...
MRSN| Name | Value |
|---|---|
| Revenues | 7.8M |
| Cost of Revenue | 0.3M |
| Gross Profit | 7.5M |
| Operating Expense | 65.6M |
| Operating I/L | -55.2M |
| Other Income/Expense | -1.0M |
| Interest Income | 2.6M |
| Pretax | -56.2M |
| Income Tax Expense | 1.0M |
| Net Income/Loss | -57.1M |
Mersana Therapeutics, Inc. is a clinical stage biopharmaceutical company specializing in the development of antibody drug conjugates (ADC) for cancer treatment. Their lead product, XMT-1592, is a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, currently in phase I clinical trials for ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate, and XMT-2056, an immunosynthen development candidate. Mersana has strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer technology.
